Mustang Bio, Inc. SEC filings MBIO
Mustang Bio, Inc. has 405 filings in SEC EDGAR's recent list, going back to Jul 28, 2016. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Dec 3, 2025 | Dec 22, 2025 |
| DEF 14C | Information statement | Mar 3, 2025 | Mar 3, 2025 |
| PRE 14C | Filing | Feb 21, 2025 | Feb 21, 2025 |
| DEF 14C | Information statement | Jan 22, 2025 | Jan 22, 2025 |
| PRE 14C | Filing | Jan 10, 2025 | Jan 10, 2025 |
| DEF 14A | Proxy statement | Dec 6, 2024 | Dec 26, 2024 |
| DEF 14C | Information statement | Jul 10, 2024 | Jul 10, 2024 |
| PRE 14C | Filing | Jun 28, 2024 | Jun 28, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 21, 2023 |
| DEF 14C | Information statement | Mar 13, 2023 | Mar 13, 2023 |
| PRE 14C | Filing | Mar 3, 2023 | Mar 3, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 21, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 17, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Jun 17, 2021 |
| DEF 14C | Information statement | Nov 13, 2020 | Nov 12, 2020 |
| PRE 14C | Filing | Oct 23, 2020 | Oct 23, 2020 |
| DEFA14A | Additional proxy material | Jun 4, 2020 | — |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 17, 2020 |
| DEF 14C | Information statement | Sep 10, 2019 | Sep 10, 2019 |
| PRE 14C | Filing | Aug 16, 2019 | Aug 16, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 18, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 14, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2018 | Jun 14, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 7, 2017 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680048
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.